Cancer vaccination with telomerase peptide GV1001

Bibliography

• Morse MA, Chui S, Hobeika A, et al. Recent developments in therapeutic cancer vaccines. Nature Clin Prac 2005;2(2):108-13
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 2006;12(10):3064-9
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10(9):909-15
   PubMed Web of Science ®Google Scholar
• Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345(6274):458-60
   PubMed Web of Science ®Google Scholar
• Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266(5193):2011-5
   PubMed Web of Science ®Google Scholar
• Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33(5):787-91
   PubMed Web of Science ®Google Scholar
• Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005;65(13):5506-11
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999;10(6):673-9
   PubMed Web of Science ®Google Scholar
• Minev B, Hipp J, Firat H, et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 2000;97(9):4796-801
   PubMed Web of Science ®Google Scholar
• Andersen MH, Svane IM, Becker JC, Straten PT. The universal character of the tumor-associated antigen survivin. Clin Cancer Res 2007;13(20):5991-4
   PubMed Web of Science ®Google Scholar
• Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer. 2008;8(3):167-79
   PubMed Web of Science ®Google Scholar
• Chiosis G. Targeting chaperones in transformed systems–a focus on Hsp90 and cancer. Expert opinion on therapeutic targets 2006;10(1):37-50
   PubMed Web of Science ®Google Scholar
• Irving J, Wang Z, Powell S, et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther 2004;11(3):174-85
   PubMed Web of Science ®Google Scholar
• Beatty GL, Vonderheide RH. Telomerase as a universal tumor antigen for cancer vaccines. Expert review of vaccines 2008;7(7):881-7
   PubMed Web of Science ®Google Scholar
• Bernhardt SL, Gjertsen MK, Trachsel S, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer 2006;95(11):1474-82
   PubMed Web of Science ®Google Scholar
• Brunsvig P, Aamdal S, Gjertsen MK, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006;55(12):1553-64
   PubMed Web of Science ®Google Scholar
• Cortez-Gonzalez X, Zanetti M. Telomerase immunity from bench to bedside: round one. J Trans Med 2007;5:12
   PubMed Web of Science ®Google Scholar
• Domchek SM, Recio A, Mick R, et al. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res 2007;67(21):10546-55
   PubMed Web of Science ®Google Scholar
• Haining WN, Davies J, Kanzler H, et al. CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res 2008;14(17):5626-34
   PubMed Web of Science ®Google Scholar
• Bolonaki I, Kotsakis A, Papadimitraki E, et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 2007;25(19):2727-34
   PubMed Web of Science ®Google Scholar
• Mavroudis D, Bolonakis I, Cornet S, et al. A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies. Oncology 2006;70(4):306-14
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Riley JP, Igarashi T, et al. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 2004;10(14):4688-98
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Yang BK, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005;174(6):3798-807
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Domchek SM, Schultze JL, et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 2004;10(3):828-39
   PubMed Web of Science ®Google Scholar
• Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003;421(6925):852-6
   PubMed Web of Science ®Google Scholar
• Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003;300(5617):337-9
   PubMed Web of Science ®Google Scholar
• Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005;54(8):721-8
   PubMed Web of Science ®Google Scholar
• Kokhaei P, Palma M, Hansson L, et al. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Exp Hematol 2007;35(2):297-304
   PubMed Web of Science ®Google Scholar
• Nava-Parada P, Emens LA. GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers. Current Opin Mol Ther 2007;9(5):490-7
   PubMed Web of Science ®Google Scholar
• Pharmexa stops one of two phase III trials. Pharmexa AS press release 2008 May 13
   Google Scholar
• GV 1001 Telovac trial is progressing according to plan. Pharmexa AS press release 2008 December 19
   Google Scholar
• Quirt I, Verma S, Petrella T, et al. Temozolomide for the treatment of metastatic melanoma: a systematic review. The Oncologist 2007;12(9):1114-23
   PubMed Web of Science ®Google Scholar
• Pharmexa provides update on the development of GV1001. Pharmexa AS press release 2007 November 19
   Google Scholar
• Kyte JA. Unconventional cytokine profiles and development of T cell memory in long term survivors after cancer vaccination. Canc Immunol Immunother 2009; [Epub ahead of print Feb 17]
   Google Scholar
• Kyte JA, Mu L, Aamdal S, et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 2006;13(10):905-18
   PubMed Web of Science ®Google Scholar
• Kyte JA, Kvalheim G, Lislerud K, et al. T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunol Immunother 2007;56(5):659-75
   PubMed Web of Science ®Google Scholar
• Chen YX, Man K, Ling GS, et al. A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by DC devoid of IL-10. J Immunol 2007;179(9):6009-15
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Szczepanski M, et al. A unique subset of CD4+CD25 high Foxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007 Aug 1;13(15 Pt 1):4345-54
   Google Scholar
• Vence L, Palucka AK, Fay JW, et al. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci USA 2007;104(52):20884-9
   PubMed Web of Science ®Google Scholar
• Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer cell 2002;2(4):257-65
   PubMed Web of Science ®Google Scholar
• Roth A, Yssel H, Pene J, et al. Telomerase levels control the lifespan of human T lymphocytes. Blood 2003;102(3):849-57
   PubMed Web of Science ®Google Scholar
• Blasco MA. Telomere length, stem cells and aging. Nature Chemical Biol 2007;3(10):640-9
   PubMed Web of Science ®Google Scholar
• Danet-Desnoyers GA, Luongo JL, Bonnet DA, et al. Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. Exp Hematol 2005;33(11):1275-80
   PubMed Web of Science ®Google Scholar
• Kyte JA, Gaudernack G. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol Immunother 2006;55(11):1432-42
   PubMed Web of Science ®Google Scholar
• Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest 2003;21(6):873-86
   PubMed Web of Science ®Google Scholar
• Lurquin C, Lethe B, De Plaen E, et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005;201(2):249-57
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136(7):2348-57
   PubMed Web of Science ®Google Scholar
• Chaouat G, Ledée-Bataille N, Dubanchet S, et al. TH1/TH2 paradigm in pregnancy: paradigm lost? Int Arch Allergy Immunol 2004 Jun;134(2):93-119
   Google Scholar
• Gor DO, Rose NR, Greenspan NS. TH1-TH2: a procrustean paradigm. Nat Immunol 2003;4(6):503-5
   PubMed Web of Science ®Google Scholar
• Darrah PA, Patel DT, De Luca PM, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007;13(7):843-50
   PubMed Web of Science ®Google Scholar
• Duvall MG, Precopio ML, Ambrozak DA, et al. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol 2008;38(2):350-63
   PubMed Web of Science ®Google Scholar
• Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006;107(12):4781-9
   PubMed Web of Science ®Google Scholar